NEWS

Written By: Pedro C. Barata, MD, Tulane University DOWNLOAD HERE   Description: The purpose of this PQI is to review the clinical considerations around the use of tivozanib (Fotivda®) for patients with relapse or refractory advanced renal cell carcinoma.   Background: Tivozanib is a small molecule that inhibits the phosphorylation of vascular endothelial growth factor […]

Written by: Andrew Ruplin, PharmD, Seattle Cancer Care Alliance Download Here The purpose of this PQI is to understand the management techniques and interventions when utilizing enfortumab vedotin.

FOR IMMEDIATE RELEASE January 12, 2022 Contact: Katie Edmiston | Marketing Manager (813) 843-1629 Katie.Edmiston@ncoda.org NCODA WELCOMES NEW EXECUTIVE COUNCIL MEMBERS   CAZENOVIA, NY – NCODA today announced the appointment of four new members to the Executive Council. With the growth of NCODA, the Executive Council has been instrumental in facilitating a strong path forward […]

Written By: Hassaan Shaikh, PharmD & Emily Brugioni, MD, University Health DOWNLOAD HERE Description: The purpose of this PQI is a summary of the process for initiating and monitoring oral temozolomide therapy in patients with Glioblastoma Multiforme (GBM). Background: GBM is the most common primary malignant brain tumor in adults and comprises 54 % of […]

FOR IMMEDIATE RELEASE January 3rd 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS   Throughout 2021 NCODA highlighted states throughout the country that took great strides to regulate Pharmacy […]

Written by: Jessie Signorelli PharmD, BCOP, Massachusetts General Hospital DOWNLAD HERE Description: This PQI will aim to review ponatinib efficacy and safety data as well as clinical pearls regarding supportive care and adverse event management.1 Background: Ponatinib (Iclusig®) is a third-generation tyrosine kinase inhibitor (TKI) with activity directed at BCR-ABL mutant kinase in patients with […]

Written by: Sara Moran Smith, PharmD, BCOP | M Health Fairview DOWNLOAD HERE Purpose: Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR)  inhibitors1 with 10-20% developing severe eruption.1 Studies have shown that the presence of this rash is indicative of response to treatment.1 Therefore, it is important to prevent […]

Written by: Dan Hertz, PharmD, PhD – University of Michigan College of Pharmacy DOWNLOAD HERE Description: The purpose of this PQI is to review recommendations for DPYD testing prior to initiation of treatment with fluoropyrimidine based chemotherapy and increase awareness of the clinical benefit of pre-treatment DPYD testing.  Background: Fluoropyrimidine (5-fluorouracil or capecitabine) chemotherapy is […]

Written By: Julia Stevens, PharmD, BCOP and Emmeline Academia, PharmD, BCOP – Beth Israel Deaconess Medical Center DOWNLOAD HERE Description: Fibroblast growth factor receptor (FGFR) inhibitors are a class of oral oncolytics approved for certain FGFR-altered malignancies, including bladder cancer (erdafitinib) and cholangiocarcinoma (infigratinib and pemigatinib). FGFR inhibitors come with unique adverse effect profiles and […]

Written By: Neal Dave, PharmD, and Natasha Khrystolubova, RPh, BCOP Download Here Description: Management of adverse effects related to regorafenib treatment in metastatic colorectal cancer. Optimal dosing and follow up are essential to help patients benefit fully while taking this medication. Background: Regorafenib is a multikinase inhibitor that has shown an overall survival benefit (6.4 […]

November 12, 2021   Statement From NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org FOR IMMEDIATE RELEASE   Comment On Proposed LCD DL37810 Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms: Optimizing Management of Patients in Underserved and Minority Populations   CAZENOVIA, […]

Written by: Michelle Hoa and Natasha Heimbigner, PharmD – Summit Cancer Centers Download Here Description: Patients undergoing cancer treatment are more susceptible to infections due to their compromised immune system. This PQI will review which vaccinations cancer patients can or cannot use for the proper protection against preventable infections. Background: Cancer treatments weaken the immune […]